Home Sulfos 1,3-Propanedisulfonic acid

1,3-Propanedisulfonic acid

CAS No.:
21668-77-9
Catalog Number:
AG003PXN
Molecular Formula:
C3H8O6S2
Molecular Weight:
204.2220
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
10g
1 week
United States
$153
- +
Product Description
Catalog Number:
AG003PXN
Chemical Name:
1,3-Propanedisulfonic acid
CAS Number:
21668-77-9
Molecular Formula:
C3H8O6S2
Molecular Weight:
204.2220
MDL Number:
MFCD00191482
IUPAC Name:
propane-1,3-disulfonic acid
InChI:
InChI=1S/C3H8O6S2/c4-10(5,6)2-1-3-11(7,8)9/h1-3H2,(H,4,5,6)(H,7,8,9)
InChI Key:
MGNVWUDMMXZUDI-UHFFFAOYSA-N
SMILES:
OS(=O)(=O)CCCS(=O)(=O)O
UNII:
6QFP76V7S7
Properties
Complexity:
254  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
203.976g/mol
Formal Charge:
0
Heavy Atom Count:
11  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
204.211g/mol
Monoisotopic Mass:
203.976g/mol
Rotatable Bond Count:
4  
Topological Polar Surface Area:
126A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
-1.6  
Literature
Title Journal
[New trends in the treatment of amyloidosis]. Medicina clinica 20120526
Counterion condensation in short cationic peptides: limiting mobilities beyond the Onsager-Fuoss theory. Electrophoresis 20120301
Review of eprodisate for the treatment of renal disease in AA amyloidosis. International journal of nephrology and renovascular disease 20120101
Preclinical development of siRNA therapeutics for AL amyloidosis. Gene therapy 20111201
Renal amyloidosis in children. Pediatric nephrology (Berlin, Germany) 20110801
Renal amyloidosis: current views on pathogenesis and impact on diagnosis. Contributions to nephrology 20110101
Two cationic metal-organic frameworks based on cadmium and α,ω-alkanedisulfonate anions and their photoluminescent properties. Dalton transactions (Cambridge, England : 2003) 20101214
[Amyloidosis in rheumatic diseases]. Annales Academiae Medicae Stetinensis 20100101
[Diagnostics and therapy of AA amyloidosis]. Der Pathologe 20090501
Eprodisate in amyloid A amyloidosis: a novel therapeutic approach? Expert opinion on pharmacotherapy 20080801
[A new treatment of renal disease in AA amyloidosis...and not only that?]. Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia 20080101
Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC neuroscience 20080101
Amyloid deposition in transplanted human pancreatic islets: a conceivable cause of their long-term failure. Experimental diabetes research 20080101
Eprodisate slows the progression of renal disease in patients with AA amyloidosis. Nature clinical practice. Nephrology 20071101
Eprodisate in AA amyloidosis. The New England journal of medicine 20070913
Eprodisate for the treatment of renal disease in AA amyloidosis. The New England journal of medicine 20070607
Advances in the treatment of amyloidosis. The New England journal of medicine 20070607
Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 20070601
[Multisystemic amyloidosis in 2007]. La Revue de medecine interne 20070501
Dissimilation of C3-sulfonates. Archives of microbiology 20060301
Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. Journal of neurochemistry 20020501
Ethanedisulfonate is degraded via sulfoacetaldehyde in Ralstonia sp. strain EDS1. Archives of microbiology 20010701
Properties